Moreover, Neuschwander-Tetri et al. demonstrated that a FXR agonist, obeticholic acid (OCA), can significantly improve the pathological outcomes of NASH and thus can be used as a potential treatment [16]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.